A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia (NCT01626885) | Clinical Trial Compass
CompletedPhase 2/3
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
Japan42 participantsStarted 2012-05
Plain-language summary
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.
Who can participate
Age range20 Years – 64 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Written informed consent obtained from the patient before the initiation of any study-specific procedures
* Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
* Patients who receive 1 or more antipsychotic drugs
* Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)
Exclusion Criteria:
* Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
What they're measuring
1
Number of Participants With Adverse Events as a Measure of Safety and Tolerability